中国医疗集团(08225.HK):百为乐赢得第四次全国药品集中采购
中国医疗集团(08225.HK)表示,集团过敏疾病拜敏临床研究中心提供临床研究和医学服务的产品百为乐(氯雷他定片),於2月3日赢得国家第四次全国药品集中采购,在全国等级医院中标,预期有助集团临床研究和医学服务增长。
集团透露,目前每十个抗敏药物有六个以上由拜敏临床研究中心负责完成,将负责一系列抗过敏、哮喘和鼻炎RWS-THERAPY和CRCO平台开展上市後真实世界临床研究,相信将对收入产生积极影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.